KRAS and adenocarcinoma: An evaluation of therapeutically targetable mutations such as EGFR, ALK, and KRAS, as well as chromosomal rearrangement and fusion of EML4, identified increasing odds of presenting these mutations in adenocarcinoma and NS compared to NSCLC and smokers, respectively.